COMy 2023 | Comparing next-generation flow and next-generation sequencing for MRD assessment in myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on the use of next-generation flow (NGF) versus next-generation sequencing (NGS) for measurable residual disease (MRD) assessment in multiple myeloma. Dr Paiva explains that NGF with the EuroFlow protocols and NGS with the clonoSEQ® platform both provide highly robust and comparable prognostic information. Dr Paiva notes, however, that each technique has different requirements, and selection should be made according to the resources and samples available. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
